Your browser doesn't support javascript.
loading
Determinants of health-related quality of life and global functioning and health in axSpA, pSpA, and PsA: results from the ASAS-PerSpA study.
Santos, Helena; Henriques, Ana R; Machado, Pedro M; Lopez-Medina, Clementina; Dougados, Maxime; Canhão, Helena; Rodrigues, Ana M; Pimentel-Santos, Fernando M.
  • Santos H; Nova Medical School, Instituto Português de Reumatologia, Lisbon, Portugal. EpiDoc Unit-CEDOC, Lisbon, Portugal.
  • Henriques AR; Nova Medical School, EpiDoc Unit-Comprehensive Health Research Center, Lisbon, Portugal.
  • Machado PM; Centre for Rheumatology and Department of Neuromuscular Diseases, University College of London, London, UK.
  • Lopez-Medina C; University Hospital Reina Sofia, Córdoba, Spain. IMIBIC, University of Córdoba, Córdoba, Spain.
  • Dougados M; COI: personal grants from UCB Pharma, Eli Lilly, Abbvie, Novartis and Janssen.
  • Canhão H; Rheumatology Department, Cochin Hospital, Paris, France.
  • Rodrigues AM; Nova Medical School, Lisbon, Portugal. CHULC-Centro Hospitalar de Lisboa Central, EpiDoc Unit-Comprehensive Health Research Center, Lisbon, Portugal.
  • Pimentel-Santos FM; Nova Medical School, Lisbon, Portugal, Rheumatology Department Hospital dos Lusíadas, EpiDoc Unit-Comprehensive Health Research Center, Lisbon, Portugal.
Article en En | MEDLINE | ID: mdl-37738594
ABSTRACT

OBJECTIVES:

We aim to identify determinants of health-related quality of life (HRQoL) and global functioning and health (GH) in axial spondyloarthritis (axSpA), peripheral spondyloarthritis (pSpA), and psoriatic arthritis (PsA).

METHODS:

ASAS-perSpA study data were analyzed. Models for the three patient groups were performed separately to explore factors associated with HRQoL and GH, assessed by EQ-5D and ASAS-HI, respectively.

RESULTS:

The analyses included 4185 patients 2719 with axSpA, 433 with pSpA, and 1033 with PsA.In axSpA, disease activity (DA) (ß=-0.061), physical function (ß=-0.041), female sex (ß=-0.019), and fibromyalgia (ß=-0.068) were associated with worse HRQoL; age (ß = 0.001) and university education (ß = 0.014) with better HRQoL. In pSpA, DA (ß=-0.04) and physical function (ß=-0.054) were associated with worse HRQoL. In PsA, DA (ß=-0.045), physical function (ß=-0.053), axial disease (ß=-0.041), and female sex (ß=-0.028) were associated with worse HRQoL.In axSpA, DA (ß = 0.889), physical function (ß = 0.887), peripheral disease (ß = 0.564), female sex (ß = 0.812) and fibromyalgia (ß = 1.639) were associated with worse GH; age (ß=-0.013) and university education (ß=-0.274) with better GH. In pSpA, physical function (ß = 1.142), and female sex (ß = 1.060) were associated with worse GH; university education (ß=-0.611) with better GH. In PsA, DA (ß = 0.703), physical function (ß = 1.025), axial involvement (ß = 0.659), female sex (ß = 0.924), and fibromyalgia (ß = 1.387) were associated with worse GH; age (ß=-0.024) and university education (ß=-0.856) with better GH.

CONCLUSIONS:

DA and physical function are major HRQoL and GH determinants across spondyloarthritis types, and clinical characteristics and sociodemographic factors play an important role, highlighting the importance of a holistic approach for individual patients.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2023 Tipo del documento: Article